Varun Vendra

Varun Vendra

Auto-generated profile, based on publicly available information

Varun Vendra

Department of Otolaryngology, Kaiser Permanente, Irvine, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Purpose: Neoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preoperative window confers survival benefit in patients with operable head and neck squamous cell carcinoma (HNSCC). Patients and Methods: A pooled analysis of treatment-naïve patients with operable HNSCC enrolled in one of three clinical trials from 2009 to 2020 (NCT00779389, NCT01218048, NCT02473731). Neoadjuvant regimens consisted of EGFR inhibitors (n = 83) or anti-ErbB3 antibody therapy (n = 9) within 28 days of surgery. Clinical to pathologic stage migration was compared with disease-free survival (DFS) and overall survival (OS) while adjusting for confounding factors using multivariable Cox regression. Circulating tumor markers validated in other solid tumor models were analyzed. Results: 92 of 118 patients were analyzed; all patients underwent surgery following neoadjuvant therapy. Clinical to pathologic downstaging was more frequent in patients undergoing neoadjuvant targeted therapy compared with control cohort (P = 0.048). Patients with pathologic downstage migration had the highest OS [89.5%; 95% confidence interval (CI), 75.7–100] compared with those with no stage change (58%; 95% CI, 46.2–69.8) or upstage (40%; 95% CI, 9.6–70.4; P = 0.003). Downstage migration remained a positive prognostic factor for OS (HR, 0.22; 95% CI, 0.05–0.90) while adjusting for measured confounders. Downstage migration correlated with decreased circulating tumor markers, SOX17 and TAC1 (P = 0.0078). Conclusions: Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

14 February 2024 in Head & Neck
Verified
Journal Article
Open access
MMMarco Mascarella
Marco Mascarella
JFJannatul Ferdus
Jannatul Ferdus
VVVarun Vendra
Varun Vendra
SSShaum Sridharan
Shaum Sridharan
KSKhalil Sultanem
Khalil Sultanem
MKMarie‐Jeanne Kergoat
Marie‐Jeanne Kergoat
Sarcopenia is an increasingly recognized biomarker associated with poorer outcomes. The objective of this study was to ascertain the effect of sarcopenia on treatment tolerance and short‐term toxicity in head and neck cancer (HNC). A systematic review was performed using multiple databases. An inverse‐variation, random‐effects model was used to perform the meta‐analysis to evaluate the effect of sarcopenia on severe treatment toxicity and poor treatment tolerance. Sixteen observational studies, including 3187 patients with HNC, were analyzed. The combined odds ratio (OR) for severe treatment toxicity and tolerance was 2.22 (95%CI 1.50–3.29) and 1.40 (95%CI 0.84–2.32), respectively. The effect of sarcopenia on short‐term severe treatment toxicity was similar with upfront surgery (OR 2.03, 95%CI 1.22–3.37) and definitive radiotherapy (OR 2.24, 95%CI 1.18–4.27) Patients with sarcopenia are more than twice as likely to suffer a short‐term treatment‐related toxicity when undergoing curative‐intent HNC treatment.

29 March 2026 in Oral Oncology
Verified
Journal Article
Open access
MMMarco Mascarella
Marco Mascarella
AMAlex Mlynarek
Alex Mlynarek
KRKeith Richardson
Keith Richardson
VVVarun Vendra
Varun Vendra
MSMario Solari
Mario Solari
MKMarie-Jeanne Kergoat
Marie-Jeanne Kergoat
Head and neck cancer (HNC) treatment often involves multimodal regimens, with 30-40% of patients experiencing significant toxicity or treatment intolerance. Existing risk models do not fully capture the complex interplay of sarcopenia, frailty, and treatment factors, limiting their utility for surgical decision-making. We developed and validated the modified Head and Neck Surgery Risk Index (mHNSRI), a tool incorporating multimodal domains of sarcopenia (cervical paraspinal skeletal muscle index, SMI), frailty (modified Frailty Index, Clinical Risk Analysis Index) and treatment factors, using an ambispective cohort of patients with operable HPV-negative stage II-IV HNC. Treatment intolerance was defined as a severe toxicity or therapy non-completion. Logistic regression and recursive partitioning analysis were used to identify predictors variables for treatment intolerance. The mHNSRI's performance was compared to traditional preoperative risk indices using internal and external validation cohorts. In 568 patients, including 343 in the derivation and 225 in the validation cohort, the mean age was 65 with 228 (40%) patients being frail and 259 (46%) sarcopenic. Treatment intolerance occurred in 270 (48%) patients. Independent predictors of treatment intolerance included low cervical paraspinal SMI, elevated Risk Analysis Index (RAI), reduced high-to-low attenuation SMI ratio and obesity. Sarcopenia and frailty had a synergistic effect on treatment intolerance. Adding cervical paraspinal SMI and high-to-low attenuation SMI ratio improved model performance (Δc-statistic 0.069, P = 0.05). The mHNSRI had an AUC of 0.71 (95% CI:0.61-0.80) in external validation cohort and demonstrated superior predictive ability compared to the RAI (Δc 0.14, modified Frailty Index-5 (Δc 0.13), ASA (Δc 0.2) and Charlson Comorbidity Index (Δc 0.14, all P < 0.05) CONCLUSION: The mHNSRI offers a personalized approach to preoperative risk stratification in HNC surgery, integrating sarcopenia and frailty metrics to better predict treatment intolerance.

25 November 2025
Verified
Other
Open access
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Comparison of clinical to pathologic stage migration between patients enrolled in 1 of 4 window trials compared to a control group

25 November 2025
Verified
Other
Open access
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Comparison of clinical to pathologic stage migration between patients enrolled in 1 of 4 window trials compared to a second control group

1 April 2023
Verified
Other
Open access
MMMarco Mascarella
Marco Mascarella
TOTolani F. Olonisakin
Tolani F. Olonisakin
PRPurva Rumde
Purva Rumde
VVVarun Vendra
Varun Vendra
MNMelonie A. Nance
Melonie A. Nance
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Comparison of clinical to pathologic stage migration between patients enrolled in 1 of 4 window trials compared to a control group